FOSRENOL TABLET (CHEWABLE)

Country: কানাডা

ভাষা: ইংরেজি

সূত্র: Health Canada

সক্রিয় উপাদান:

LANTHANUM (LANTHANUM CARBONATE HYDRATE)

থেকে পাওয়া:

TAKEDA CANADA INC

এটিসি কোড:

V03AE03

INN (International Name):

LANTHANUM CARBONATE

ডোজ:

750MG

ফার্মাসিউটিকাল ফর্ম:

TABLET (CHEWABLE)

রচনা:

LANTHANUM (LANTHANUM CARBONATE HYDRATE) 750MG

প্রশাসন রুট:

ORAL

প্যাকেজ ইউনিট:

15G/50G

প্রেসক্রিপশন টাইপ:

Prescription

Therapeutic area:

PHOSPHATE-REMOVING AGENTS

পণ্য সারাংশ:

Active ingredient group (AIG) number: 0151709003; AHFS:

অনুমোদন অবস্থা:

APPROVED

অনুমোদন তারিখ:

2007-10-04

পণ্য বৈশিষ্ট্য

_ _
_ _
_FOSRENOL_
_®_
_ Product Monograph _
_Page 1 of 32_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
FOSRENOL®
lanthanum carbonate hydrate
Chewable tablets, 250 mg, 500 mg, 750 mg, and 1000 mg, oral
Phosphate binder
ATC code: V03A E03
Takeda Canada Inc.
22 Adelaide Street West,
Suite 3800
Toronto Ontario M5H 4E3
Date of Initial Authorization:
December 14, 2012
Date of Revision:
April 06, 2023
Submission Control Number:
270959
FOSRENOL® and the FOSRENOL Logo are registered trademarks of Shire
International Licensing BV, a
Takeda company. TAKEDA® and the TAKEDA Logo are registered trademarks
of Takeda Pharmaceutical
Company Limited, used under license.
_ _
_ _
_ _
_FOSRENOL_
_®_
_ Product Monograph _
_Page 2 of 32_
RECENT MAJOR LABEL CHANGES
7 WARNINGS AND PRECAUTIONS, Gastrointestinal
04/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED
.
[To update, right-click anywhere in the Table of Contents and select
“Update Field”, “Update entire
table”, click OK.]
RECENT MAJOR LABEL CHANGES
............................................................................................
2
TABLE OF CONTENTS
..............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................................
4
1
INDICATIONS
...............................................................................................................
4
1.1
Pediatrics
................................................................................................................
4
1.2
Geriatrics
................................................................................................................
4
2
CONTRAINDICATIONS
.................................................................................................
4
4
DOSAGE AND ADMINISTRATION
.................................................................................